血管紧张素II受体2型在乳腺癌患者中的表达及生物学意义
Expression and Biological Significanceof Angiotensin II Receptor Type 2 in Breast Cancer Patients
DOI: 10.12677/ACM.2021.1110641, PDF,    科研立项经费支持
作者: 李 健*：泰安市中心医院，山东 泰安；王 颜#：山东农业大学，山东 泰安
关键词: 乳腺癌；血管紧张素II受体2型(AGTR2)；预后；免疫浸润；Breast Cancer； Angiotensin II Receptor Type 2 (AGTR2)； Prognosis； Immune Infiltration
摘要: 目的：运用生物信息学的方法探讨血管紧张素II受体2型(AGTR2)基因在乳腺癌患者中的表达、预后意义及与免疫浸润之间的关系。方法：我们在多个数据库中探讨了AGTR2在乳腺癌中的表达模式和预后价值，包括Ualcan、Bc-GenExMiner v4.7和Kaplan-Meier Plotter数据库。然后，我们使用TIMER数据库研究了乳腺癌中AGTR2表达和免疫细胞浸润之间的相关性。结果：我们发现乳腺癌肿瘤组织中AGTR2的表达水平显著低于癌旁组织，AGTR2的高表达水平有助于乳腺癌患者的生存。在乳腺癌中，AGTR2表达与多种免疫细胞(包括CD8+ T细胞、CD4+ T细胞)之间存在显著正相关(p < 0.05)，与肿瘤纯度显著负相关(p < 0.05)。总之，AGTR2可作为乳腺癌的预后生物标志物，并可能与免疫细胞浸润相关。
Abstract: Objective: Bioinformatics methods were used to investigate the gene expression of angiotensin II receptor type 2 (AGTR2), its prognostic significance and relationship with immune cell infiltration in breast cancer patients. Methods: We explored the expression pattern and prognostic value of AGTR2 in breast cancer in multiple databases, including Ualcan, Bc-GenExMiner v4.7 and Kaplan-Meier Plotter databases. Then, the TIMER database was used to study the correlation between AGTR2 expression and immune cell infiltration in breast cancer. Results: We found that the expression level of AGTR2 in breast cancer tumor tissues was significantly lower than that in adjacent tissues. The high expression level of AGTR2 contributes to the survival of breast cancer patients. In breast cancer, AGTR2 expression is significantly positively correlated with a variety of immune cells (including CD8+ T cells, CD4+ T cells) (p < 0.05), and significantly negatively correlated with tumor purity (p < 0.05). In short, AGTR2 can be used as a prognostic biomarker of breast cancer and is probably related to immune cell infiltration.
文章引用：李健, 王颜. 血管紧张素II受体2型在乳腺癌患者中的表达及生物学意义[J]. 临床医学进展, 2021, 11(10): 4378-4384. https://doi.org/10.12677/ACM.2021.1110641

参考文献

[1] Bray, F., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Momenimovahed, Z. and Salehiniya, H. (2019) Epidemiological Characteristics of Risk Factors for Breast Cancer in the World. Breast Cancer: Targets and Therapy, 11, 151-164. [Google Scholar] [CrossRef] 
[3] Goldhirsch, A., Winer, E.P., Coates, A.S., et al. (2011) Strategies for Subtypes—Dealing with the Diversity of Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 22, 1736-1747. [Google Scholar] [CrossRef] [PubMed]
[4] Koo, T.R., Eom, K.Y., Kang, E.Y., et al. (2013) Prognostic Value of the Nodal Ratio and Ki-67 Expression in Breast Cancer Patients Treated with Postmastectomy Radiotherapy. Journal of Breast Cancer, 16, 274-284. [Google Scholar] [CrossRef] [PubMed]
[5] 潘金鹏, 杜芯瑜, 崔鹏, 等. 高血压住院患者情况分析[J]. 临床医学进展, 2020, 10(9): 2174-2179.
[6] 李金红. 血压与癌症风险的相关性分析[J]. 抗癌之窗, 2019(4): 80-81.
[7] 李健. 高血压和肾素-血管紧张素系统阻断剂对肺癌病人结局的影响[D]: [博士学位论文]. 济南: 山东大学, 2017.
[8] Patterson, R.E., Flatt, S.W., Saquib, N., et al. (2010) Medical Comorbidities Predict Mortality in Women with a History of Early Stage Breast Cancer. Breast Cancer Research and Treatment, 122, 859-865. [Google Scholar] [CrossRef] [PubMed]
[9] Mottl, A.K., Shoham, D.A. and North, K.E. (2008) Angiotensin II Type 1 Receptor Polymorphisms and Susceptibility to Hypertension: A HuGE Review. Genetics in Medicine, 10, 560-574. [Google Scholar] [CrossRef] 
[10] Ekambaram, P., Lee, J.-Y.L., Hubel, N.E., et al. (2017) The CARMA3-Bcl10-MALT1 Signalosome Drives NF-κB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. Cancer Research, 78, 1225-1240. [Google Scholar] [CrossRef] 
[11] 王悦, 李航, 李腾越, 等. 血管紧张素II在肿瘤发病机制中的研究进展[J]. 吉林医药学院学报, 2017(6): 67-69.
[12] Ateeq, B., Tomlins, S. and Chinnaiyan, A.M. (2009) AGTR1 as a Therapeutic Target in ER-Positive and ERBB2-Negative Breast Cancer Cases. Cell Cycle, 8, 3794-3795. [Google Scholar] [CrossRef] [PubMed]
[13] Juan, D., Bofill, J.S., Ciruelos, E.M., et al. (2012) Study of the Usefulness of Angiotensin Type 1 Receptor (AGTR1) as a Possible Response Predictor in Patients with Metastatic Breast Cancer (mBC) Subjected to Chemotherapy and Treatment with Bevacizumab (AVALUZ Study). Journal of Clinical Oncology, 30, 10608.
[14] Cui, C., Huang, C., Zhou, W., et al. (2020) AGTR2, One Possible Novel Key Gene for the Entry of SARS-CoV-2 into Human Cells. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 18, 1230-1233. [Google Scholar] [CrossRef] 
[15] Acconcia, F. (2020) The Network of Angiotensin Receptors in Breast Cancer. Cells, 9, 1336. [Google Scholar] [CrossRef] [PubMed]
[16] 丁祥黎, 王海峰, 杨德林, 等. 血管紧张素II的1,2型受体在肿瘤中的作用[J]. 国际肿瘤学杂志, 2014, 41(5): 321-323.
[17] Mata-Greenwood, E., Blood, A.B., Sands, L.D., Bragg, S.L., Xiao, D. and Zhang, L. (2018) A Novel Rodent Model of Pregnancy Complications Associated with Genetically Determined Angiotensin-Converting Enzyme (ACE) Activity. The American Journal of Physiology: Endocrinology and Metabolism, 315, E52-E62. [Google Scholar] [CrossRef] [PubMed]
[18] Park, Y.A., Choi, C.H., Do, I.G., et al. (2014) Dual Targeting of Angiotensin Receptors (AGTR1 and AGTR2) in Epithelial Ovarian Carcinoma. Gynecologic Oncology, 135, 108-117. [Google Scholar] [CrossRef] [PubMed]

为你推荐